Sonnet BioTherapeutics' Chief Medical Officer to Present Cutting-Edge Research
In a much-anticipated event within the biotech community, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) is excited to announce that Dr. Richard Kenney, M.D., the Chief Medical Officer, will present at the upcoming Annual Cytokine-Based Drug Development Summit scheduled for mid-May. The event promises to showcase the latest advancements in immunotherapeutic strategies aimed at targeting the tumor microenvironment (TME).
Details of the Presentation
The presentation, titled Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic Window, will occur on May 15, at 11:15 AM ET. This session is particularly crucial as Dr. Kenney will explore innovative methodologies to enhance safety profiles of cytokine-based therapies, which have become paramount in modern oncology.
Key Discussion Points
During his session, Dr. Kenney intends to delve into several critical topics:
- Discussing strategies behind introducing receptor bias to reduce toxicity while enhancing therapeutic efficacy;
- Outlining techniques for optimizing cytokine potency and tackling their inherent toxicities, whilst considering how the therapeutic index affects clinical outcomes;
- Assessing whether toxicity is the key limiting factor in achieving therapeutic benefits and investigating other elements that may shape the ‘therapeutic window’.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is devoted to revolutionizing treatment options within oncology through its unique technology and innovative medicinal approaches. At the heart of their mission lies the FHAB (Fully Human Albumin-Binding) platform, which is crafted to utilize single chain antibody fragments that bind to human serum albumin. This enabled platform enhances the delivery of drugs specifically to tumor and lymphatic tissues, thus optimizing both safety and effectiveness for various biological drugs.
Current Programs and Developments
Sonnet’s leading therapeutic candidate, SON-1010, known as IL-12-FHAB, is currently in development for targeting solid tumors, including specific sarcomas and ovarian cancer. This promising candidate is being assessed as part of a Phase 1/2a trial conducted in partnership with Roche, aiming to combine SON-1010 with atezolizumab (Tecentriq) specifically for platinum-resistant ovarian cancer. This endeavor showcases Sonnet's commitment to collaborative research to broaden treatment accessibility.
Additionally, Sonnet is advancing its second program, SON-1210, another IL12-FHAB-IL15 candidate, which is poised to enter an investigator-initiated study targeting pancreatic cancer, demonstrating the company's strategic focus on areas of high unmet medical need.
Importance of Upcoming Presentation
As Dr. Kenney prepares for his pivotal presentation at the Annual Cytokine-Based Drug Development Summit, the insights he shares are expected to significantly influence the future of immunotherapies. His expert understanding of cytokine mechanisms plays a vital role in rethinking how clinicians can develop safer, more effective therapies. This aligns with the company’s broader goal of enhancing patient outcomes through innovative therapeutic development.
Frequently Asked Questions
What is the main focus of Dr. Kenney's presentation?
Dr. Kenney will focus on managing toxicity caused by cytokines to enlarge the therapeutic window of treatments.
When and where will the Summit take place?
The Annual Cytokine-Based Drug Development Summit will take place on May 15-16, in Boston, MA.
What platform does Sonnet use for drug development?
Sonnet employs the FHAB platform, designed to optimize the delivery of therapeutics to target tissues.
What are Sonnet’s key products currently in development?
Sonnet’s leading candidates include SON-1010 for treating solid tumors and SON-1210 for pancreatic cancer.
How can I get more information about the Summit?
Visit the Summit website for more details on sessions and speakers.
